Goldsmith Mark A's Form 4 filing
Revolution Medicines, Inc. (RVMD) · filed Jun 5, 2024
- Accession no.
- 0001610717-24-000285
- Filed
- Jun 5, 2024
- Trade date
- Jun 3, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $300.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Goldsmith Mark ACIK 0001246842 | Director, Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | Common Stock | MOption exerciseAcquired | +7,500 | $4.09 | +$30,675 | 329,822 | Direct | |
| Jun 3, 2024 | Common Stock | SSaleDisposed | −900 | $39.09F4 | −$35,181 | 328,922 | Direct | |
| Jun 3, 2024 | Common Stock | SSaleDisposed | −5,699 | $39.99F5 | −$227,903.01 | 323,223 | Direct | |
| Jun 3, 2024 | Common Stock | SSaleDisposed | −901 | $40.93F6 | −$36,877.93 | 322,322 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2024 | Common Stock | MOption exerciseDisposed | −7,500 | $0.00 | $0 | 316,229 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
This transaction was executed in multiple trades in prices ranging from $38.41 to $39.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades in prices ranging from $39.41 to $40.36, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F6
This transaction was executed in multiple trades in prices ranging from $40.50 to $41.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
President and Chief Executive Officer